Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
86.356,92
0,23%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Amneal Pharmaceuticals Inc (AMRX) Amneal Pharmaceuticals Inc (AMRX) Notizie

AMRX

Amneal Pharmaceuticals (AMRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMRX
DataOraFonteTitoloSimboloCompagnia
07/03/202522:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
05/03/202523:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
28/02/202512:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
28/02/202512:00Business WireAmneal Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
19/02/202514:00Business WireAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideNASDAQ:AMRXAmneal Pharmaceuticals Inc
29/01/202514:30Business WireAmneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025NASDAQ:AMRXAmneal Pharmaceuticals Inc
23/01/202523:49Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
23/01/202514:00Business WireAmneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for RifaximinNASDAQ:AMRXAmneal Pharmaceuticals Inc
04/12/202414:00Business WireAmneal to Participate at Upcoming Investor ConferencesNASDAQ:AMRXAmneal Pharmaceuticals Inc
21/11/202422:05Business WireAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNASDAQ:AMRXAmneal Pharmaceuticals Inc
14/11/202422:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
12/11/202422:25Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
08/11/202412:00Business WireAmneal Reports Third Quarter 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
31/10/202423:51Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
21/10/202414:00Business WireAmneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release TabletsNASDAQ:AMRXAmneal Pharmaceuticals Inc
08/10/202422:05Business WireAmneal to Report Third Quarter 2024 Results on November 8, 2024NASDAQ:AMRXAmneal Pharmaceuticals Inc
01/10/202412:00Business WireAmneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic DiseasesNASDAQ:AMRXAmneal Pharmaceuticals Inc
09/08/202422:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMRXAmneal Pharmaceuticals Inc
13/05/202422:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
25/01/202413:30GlobeNewswire Inc.Knight Therapeutics Enters into Exclusive License Agreement with Amneal Pharmaceuticals for IPX203NASDAQ:AMRXAmneal Pharmaceuticals Inc
05/01/202422:09Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AMRXAmneal Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AMRX

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
LDO
Leonardo
BIT
STLAM
Stellantis NV
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
RACE
Ferrari NV
BIT
SFER
Salvatore Ferragamo
BIT
MONC
Moncler
BIT
AMP
Amplifon
BIT
CPR
Davide Campari
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
BAMI
Banco BPM
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
STMMI
ST Microelectronics
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci